A novel nomogram for predicting endoscopic remission in refractory Crohn's disease with ustekinumab administration
Rev Esp Enferm Dig. 2024 Jan 18. doi: 10.17235/reed.2024.10212/2023. Online ahead of print.ABSTRACTUstekinumab (UST) is a human IgG1 monoclonal antibody that targets to the share p40 subunit of interleukin-12(IL-12) and IL-23. Evidence has shown that UST therapy is well tolerated and effective in inducing clinical response in refractory CD(Crohn's disease) and dose escalation is effective in recapturing response in over half of the patients. However, no predictive factor has been reported to be helpful for UST treatment in clinical practice. Additionally, there were few reports about therapeutic drug monitoring (TDM) of US...
Source: Revista Espanola de Enfermedades Digestivas - January 18, 2024 Category: Gastroenterology Authors: Sucong Lyu Guoqiang Zhong Yangda Song Yan Sun Jin Li Xiujing Fan Qing Qing Mingsong Li Source Type: research
Clinical Update on the Prevention and Management of Postoperative Crohn ’s Disease Recurrence
AbstractPurpose of ReviewDespite advances in therapeutics, a significant portion of patients with Crohn ’s disease still require surgical management. In this article, we present updates to the natural history, prognostication and postoperative monitoring, and novel therapeutics in the prevention and treatment of postoperative Crohn’s disease recurrence.Recent FindingsClinical risk factors have been associated with higher rates of postoperative recurrence (POR), and in recent studies demonstrate an increased cumulative risk with presence of additional risk factors. Additional novel clinical, histologic, and “-omic” ...
Source: Current Gastroenterology Reports - January 16, 2024 Category: Gastroenterology Source Type: research
A bibliometric and visual analysis of the use of ustekinumab in Crohn ’s disease using CiteSpace
Conclusion: The number of clinical studies involving the outcome of UST treatment in CD patients has increased, with the current research focusing on efficacy, safety, indications for vulnerable populations, therapeutic drug monitoring, and biomarkers. As an alternative drug after the failure of traditional immunosuppressive therapies or TNF-α antagonist therapy, UST is an effective and safe therapy in real-world refractory CD patients. UST will remain an active candidate for research in the treatment of CD. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - January 10, 2024 Category: Drugs & Pharmacology Source Type: research
Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease
Limited data are available on the consequences of prenatal exposure to vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and ustekinumab with that of anti-TNF, in pregnant women with inflammatory bowel diseases (IBD). (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - January 8, 2024 Category: Gastroenterology Authors: Antoine Meyer, Sara Miranda, J érôme Drouin, Alain Weill, Franck Carbonnel, Rosemary Dray-Spira Source Type: research
Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study
CONCLUSION: This study demonstrated bioequivalence of SB17, EU-UST, and US-UST in terms of PK. Safety, tolerability, and immunogenicity were also comparable between all groups.PMID:38174886 | DOI:10.5414/CP204492 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - January 4, 2024 Category: Drugs & Pharmacology Authors: Hansol Jeong Taeseung Kang Jiyoon Lee Seongsik Im Source Type: research
Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study
CONCLUSION: This study demonstrated bioequivalence of SB17, EU-UST, and US-UST in terms of PK. Safety, tolerability, and immunogenicity were also comparable between all groups.PMID:38174886 | DOI:10.5414/CP204492 (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - January 4, 2024 Category: Drugs & Pharmacology Authors: Hansol Jeong Taeseung Kang Jiyoon Lee Seongsik Im Source Type: research
Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study
CONCLUSION: This study demonstrated bioequivalence of SB17, EU-UST, and US-UST in terms of PK. Safety, tolerability, and immunogenicity were also comparable between all groups.PMID:38174886 | DOI:10.5414/CP204492 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - January 4, 2024 Category: Drugs & Pharmacology Authors: Hansol Jeong Taeseung Kang Jiyoon Lee Seongsik Im Source Type: research
Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study
CONCLUSION: This study demonstrated bioequivalence of SB17, EU-UST, and US-UST in terms of PK. Safety, tolerability, and immunogenicity were also comparable between all groups.PMID:38174886 | DOI:10.5414/CP204492 (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - January 4, 2024 Category: Drugs & Pharmacology Authors: Hansol Jeong Taeseung Kang Jiyoon Lee Seongsik Im Source Type: research
Use of real-world data to assess the effectiveness of ustekinumab in treating IBD patients: a retrospective linked database study in northwest London
Volume 23, Issue 12, July - December 2023, Page 1317-1329 . (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - December 28, 2023 Category: Drugs & Pharmacology Authors: Nik KamperidisMoulesh ShahSophie YoungEvgeniy GalimovShruti SweeneyNaila Arebia Department of Gastroenterology, St Marks Hospital, London, UKb Imperial College Health Partners, London, UKc Janssen Cilag Limited, High Wycombe, UK Source Type: research
Biologics for inherited disorders of keratinisation: A systematic review
CONCLUSIONS: Whilst biologics may be considered in cases of inherited keratinisation disorders recalcitrant to standard therapy, definitive conclusions are prohibited by the low-level of evidence and substantial heterogeneity in methodology across the included studies. Establishment of consensus definitions, and randomised clinical trials may help ascertain the efficacy and safety of biologic therapy in this context and establish the best agent and dosing protocol for each disorder.PMID:38126177 | DOI:10.1111/ajd.14197 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - December 21, 2023 Category: Dermatology Authors: Michelle K Y Chen Alice L Flanagan Deshan F Sebaratnam Yaron Gu Source Type: research
